Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.

Hematology/oncology clinics of North America - 1 Jun 2023

Brea Elliott, Rotow Julia

Abstract excerpt

This article provides an updated review of the management of oncogene-driven non-small cell lung cancer. The use of targeted therapies for lung cancer driven by EGFR, ALK, ROS1, RET, NTRK, HER2, BRAF, MET, and KRAS are discussed, both in the first-line setting and in the setting of acquired resistance.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 37024384
DOI: 10.1016/j.hoc.2023.02.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.PMID 37024384Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy of non-small cell lung cancer.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Molecular therapeutic targets in non-small cell lung cancer.Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.